These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The big clinical trials in idiopathic pulmonary fibrosis. Luppi F; Spagnolo P; Cerri S; Richeldi L Curr Opin Pulm Med; 2012 Sep; 18(5):428-32. PubMed ID: 22759771 [TBL] [Abstract][Full Text] [Related]
7. Current clinical trials for the treatment of idiopathic pulmonary fibrosis. Klingsberg RC; Mutsaers SE; Lasky JA Respirology; 2010 Jan; 15(1):19-31. PubMed ID: 20199632 [TBL] [Abstract][Full Text] [Related]
8. Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. Homma S; Sugino K; Sakamoto S Respir Investig; 2015 Jan; 53(1):7-12. PubMed ID: 25542598 [TBL] [Abstract][Full Text] [Related]
10. [Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis]. Bonella F; Wessendorf TE; Costabel U Dtsch Med Wochenschr; 2013 Mar; 138(11):518-23. PubMed ID: 23423955 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626 [TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications. Spagnolo P; Rossi G; Cavazza A Expert Rev Clin Immunol; 2014 Aug; 10(8):1005-17. PubMed ID: 24953006 [TBL] [Abstract][Full Text] [Related]
13. A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. Vancheri C; du Bois RM Eur Respir J; 2013 Feb; 41(2):262-9. PubMed ID: 22903965 [TBL] [Abstract][Full Text] [Related]
14. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis. Potts J; Yogaratnam D Ann Pharmacother; 2013 Mar; 47(3):361-7. PubMed ID: 23404802 [TBL] [Abstract][Full Text] [Related]
15. Pitfalls in developing new compounds for idiopathic pulmonary fibrosis. Nathan SD; Martinez FJ Curr Opin Pulm Med; 2017 Sep; 23(5):426-431. PubMed ID: 28771451 [TBL] [Abstract][Full Text] [Related]
16. New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research. Baroke E; Gauldie J; Kolb M Expert Rev Respir Med; 2013 Oct; 7(5):465-78. PubMed ID: 24138691 [TBL] [Abstract][Full Text] [Related]
17. Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design. O'Riordan TG; Smith V; Raghu G Chest; 2015 Oct; 148(4):1083-1092. PubMed ID: 26020856 [TBL] [Abstract][Full Text] [Related]
18. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis. Dimitroulis IA Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550 [TBL] [Abstract][Full Text] [Related]
19. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. Hilberg O; Simonsen U; du Bois R; Bendstrup E Clin Respir J; 2012 Jul; 6(3):131-43. PubMed ID: 22697264 [TBL] [Abstract][Full Text] [Related]